RADEK SKODA to Protein-Tyrosine Kinases
This is a "connection" page, showing publications RADEK SKODA has written about Protein-Tyrosine Kinases.
Connection Strength
0.908
-
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006 Aug 15; 108(4):1377-80.
Score: 0.233
-
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005 Nov 15; 106(10):3374-6.
Score: 0.221
-
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28; 352(17):1779-90.
Score: 0.217
-
The leptin receptor activates janus kinase 2 and signals for proliferation in a factor-dependent cell line. Mol Endocrinol. 1997 Apr; 11(4):393-9.
Score: 0.124
-
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006 Sep 15; 108(6):1865-7.
Score: 0.058
-
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005 Jul; 90(7):871-4.
Score: 0.055